Overview

Effect of Erenumab-aooe on Disability and Work Productivity in Employed Subjects With Episodic Migraine

Status:
Terminated
Trial end date:
2021-07-26
Target enrollment:
Participant gender:
Summary
To evaluate the effect of erenumab compared to placebo on disability in employed subjects with episodic migraine (EM) who have previously failed 1 or more migraine preventive treatments.
Phase:
Phase 4
Details
Lead Sponsor:
Amgen
Collaborator:
Novartis
Treatments:
Antibodies, Monoclonal
Erenumab